To investigate whether the Agouti-related protein (Agrp), the melanocortin receptor antagonist, alters oxygen consumption, as a measure of energy expenditure. DESIGN: A 7-day intracerebroventricular administration of Agrp (1 nmol/day) in rats. MEASUREMENTS: Oxygen consumption was determined in closed-circuit respirometers on days 1 and 8. BRL-35135, a b3-adrenoreceptor agonist known to activate the brown adipose tissue (BAT) thermogenesis directly and increase core temperature, was administered i.p. (40 mg/kg) on day 9 to challenge functionally the BAT. RESULTS: Agrp treatment caused a 54% increase in daily food intake and a 12% increase in body weight. An 8% decrease in VO 2 measurements was observed following ICV Agrp treatment on day 1. A similar decrease (7%) was observed on day 8. BRL-35135 stimulated colonic temperature in control rats. However, in the rats that had previously been treated with Agrp this effect was significantly blunted. CONCLUSION: Chronic CNS administration of Agrp decreases oxygen consumption and decreases the capacity of BAT to expend energy. The obesity observed following CNS administration of Agrp is the result of decreased energy expenditure and increased food intake.
Introduction
The hypothalamic melanocortin system is a regulator of energy homeostasis (for a review see Barsh 1 ). Agouti-related protein (Agrp), produced in the arcuate nucleus (Arc), is an antagonist at the melanocortin 3 and 4 receptors (MC3/4-R). 2 Central nervous system (CNS) administration of MC3/4-R agonists (MT II or alpha MSH) decreases food intake and body weight. 1, 2 Conversely, a single injection of the MC3/4-R antagonists, Agrp, SHU9119 or HS014 stimulates food intake in rodents and chronic CNS administration leads to obesity. [2] [3] [4] [5] [6] The melanocortins appear to play a role not only in the control of food intake, but also to alter energy expenditure and may mediate some of the effects of leptin on energy homeostasis. 7 CNS administration of MT II increases oxygen consumption. 8, 9 However, the MC4-R antagonist HS024 has no such effect. 9 Alterations in energy expenditure may, in part, be regulated via the hypothalamopituitary-thyroid (HPT) axis. 10, 11 We have previously demonstrated that chronic 7-day administration of Agrp increases food intake and body adiposity. This was associated with a suppression of HPT axis and brown adipose tissue (BAT) uncoupling protein 1 (UCP-1). 12 Interestingly, these findings were also observed in an Agrp-treated group, which was 'pair fed' to the saline-injected animals suggesting that the effects were independent of the increased food intake. 12 To examine this further, we have now investigated whether acute and chronic CNS Agrp treatment alters oxygen consumption.
In vivo methods
Adult Wistar rats were cannulated into the third cerebral ventricle (ICV), handled, sham injected and acclimatised to experimental procedures as previously described. 2, [11] [12] [13] Substances were administered in a volume of 1 ml via a stainless-steel injector. 2, [11] [12] [13] The daily administration protocol and dose (1 nmol/day) were based on our previous study. 12 Osmotic minipumps were not used as we have found that peptides degrade using such methods. 13 Furthermore, pump insertion requires a general anaesthetic and a postsurgical recovery phase. Oxygen consumption (VO 2 ) was determined in closed-circuit respirometers, and colonic temperature (T c ) was measured using a rectal thermocouple probe as previously described. [14] [15] [16] Rats had been acclimatised to the procedure on two previous occasions. Results are presented as mean7s.e.m. Results were analysed by unpaired Student's t-test. Area under the curve (AUC) was calculated using the trapezoid rule. In all cases, Po0.05 was considered to be statistically significant.
Pilot study
We administered Agrp (1 nmol/day) ICV to ad libitum fed animals for 7 days. The Agrp-treated animals had increased food intake and body weight as previously observed. 12 On day 7 of treatment, we measured the VO 2 during the early light phase when the animals were satiated. A significant increase in baseline VO 2 was observed in the Agrp-treated animals. However, the Agrp-treated animals were consuming approximately double the food intake of the saline controls overnight prior to the morning study. Thus, the increase in basal VO 2 observed in the Agrp-treated group was likely to be because of an increased postprandial thermogenesis resulting from the increased overnight food intake. Therefore, we amended our study protocol to match the food intake of the experimental groups. Pair feeding the Agrp-treated animals to the saline control group was considered. However, in protocols such as this the 'pair-fed' animals are hungry, consume all the food presented to them immediately and could be considered 'food restricted'. Since either food restriction or fasting decreases oxygen consumption, 17, 18 any results obtained from this experimental design would be invalidated. Previous investigations have concluded that 12 h fasting is the most appropriate period to avoid the thermal effect of feeding without significantly stimulating energy conservation mechanisms. 19 From these results and our pilot observations, it was decided that both the experimental groups should be fasted overnight during lights out (dark phase) 12 h prior to the VO 2 measurements. However, this period of fasting lowers SNS activity and the alimentary tract of the Agrp-treated animals may not have been as empty as control rats. These should be considered when interpreting the results from our current investigation. On balance, we decided to proceed with the 12 h fast prior to the VO2 measurements as this was the only protocol where the potential effects of Agrp could be examined without the interference from differential food consumption.
Experimental protocol and results
Day 1: Fasted rats (n ¼ 8 per group) were placed in the recording chambers for 2 h (preinjected basal VO 2 ). Animals were removed and injected (1 ml) ICV with either saline or Agrp (1 nmol) (time 0). 2, 12 Colonic temperature was measured and animals were replaced in the recording chambers for a 2 h basal period (preinjection VO 2 ), and VO 2 measurements were made over the next 4 h. An 8% decrease in VO 2 measurements was observed in the 4 h following ICV Agrp treatment compared to controls (oxygen consumption as a % preinjected basal VO 2 : Agrp 104.073.0% vs saline 112.475.7%, Po0.01 vs saline and a significant (Po0.001) decrease in the AUC for the 4 h postinjection period). Colonic temperature was measured at three points over the experimental day and no changes between the Agrp-treated and control groups were observed.
The rats received daily ICV (1 ml) injections of either Agrp (1 nmol/day) or saline for the next 7 days. In agreement with our previous study, 12 there was no significant change in the body weight of the saline group (saline, day 0: 239711 g, day 7: 226714 g). However, there was a 12% increase in body weight in the Agrp-treated animals (Agrp, day 0: 24777 g, day 7: 27678 g, Po0.001 vs day 0) (Figure 1a ). Agrp significantly increased daily food intake and no escape from the effects of the treatment were observed (Figure 1b ) (food intake, day 7: Agrp 34.971.6 g vs saline 22.670.7 g, Po0.0001 vs saline). This represented a 54% increase in food intake in the Agrp-treated animals, compared to saline controls. Day 7: The rats were injected with either Agrp or saline and fasted overnight.
Day 8: Rats previously fasted for 12 h were placed in the recording chambers. Injections, VO 2 and colonic temperature measurement were performed as described above. Following administration of Agrp there was a statistically significant 7% decrease in the mean VO 2 measurements over the subsequent 4 h (mean 4 h energy expenditure (J): Agrp 271.172.2 vs saline 289.973.2, Po0.001 vs saline and a significant (Po0.0001) decrease in the AUC for the 4 h postinjection period (Figure 2a) . No change in colonic temperature was observed after the ICV injection.
Day 9: BRL-35135, b3 adrenoreceptor agonist, was administered IP (40 mg/kg) at time 0 and colonic temperature measured over the subsequent 2 h. Administration of a b3 adrenoreceptor agonist, BRL-35135, had been found to activate directly BAT thermogenesis, double BAT uncoupling protein-1 (UCP-1) mRNA and increase core temperature. 20 In the saline-treated controls, BRL-35135 increased colonic temperature by 0.570.11C (mean over the 2 h experiment). However, in the rats that had received the chronic CNS Agrp treatment there was a significant blunting of this effect and BRL-35135 increased the colonic temperature by 0.170.11C (mean over the 2 h experiment) (Figure 2b ).
Discussion
Rats receiving daily CNS administration of the MC3/4-R antagonist, Agrp, had an 8% reduction in oxygen consumpChronic Agrp reduces energy expenditure CJ Small et al tion compared to saline-injected controls. These experiments were performed in overnight fasted animals to remove the effects of increased food intake in the Agrp-treated animals. Fasted animals are known to have a lower basal oxygen consumption than fed rats. 17, 18 Agrp may have a greater effect on oxygen consumption but this was masked because of the current experimental protocol and lower basal oxygen consumption. However, a small decrease such as this causing a daily reduction in energy expenditure, together with the stimulation in food intake, may be the mechanism by which Agrp causes an increased body weight and adiposity.
In humans energy expenditure can be calculated from oxygen used in expired air using the Weirs formula. 21 In a 75 kg person, a decrease in oxygen consumption of 8% would result in a reduction in calorie requirement (for maintenance energy balance) of 700 kcal/day. However, if food intake were to stay at 2116 kcal/day (the recommended daily allowance for energy balance) with the reduction in oxygen consumption of 8%, weight gain would initially be 120 g/day until the gain in mass was sufficient to establish energy balance. In the above example, our 75 kg person would become 112.5 kg. This is a theoretical model and assumes that no adaptation to the reduced oxygen consumption has occurred. However, it does illustrate that a relatively small decrease of oxygen consumption could have profound effects on body weight. Chronic Agrp reduces energy expenditure CJ Small et al
We have previously investigated the mechanisms underlying these effects and found that both acute 11 and chronic 12 CNS administration of Agrp suppressed the HPT axis and chronic CNS treatment decreased BAT UCP-1 levels. 12 These effects were also observed in the 'pair-fed' group, suggesting that the effects were independent of food intake. In this current study, we have expanded these observations and examined the capacity of the BAT to expend energy. In control animals, administration of a b3-adrenoreceptor agonist caused a significant increase in colonic temperature. Rats treated daily with Agrp failed to increase their colonic temperature when challenged by a b3-adrenoreceptor agonist. Taken together with our previous work, this suggests that chronic CNS treatment with Agrp causes a reduction in BAT UCP-1, 12 via a suppression of the HPT axis 11, 12 and a decrease in the thermogenic capacity of BAT. Further studies are required to investigate the effect of Agrp treatment on UCP-2 and UCP-3 expression in order to extrapolate these findings in rodents to man.
In conclusion, we have found that chronic CNS administration of Agrp decreased oxygen consumption by 8% and decreased the capacity of BAT to expend energy. This could contribute to altered body weight. The reduction in oxygen consumption leading to a reduction in energy expenditure, together with stimulation in food intake, may be the mechanism by which Agrp causes obesity.
